Pages that link to "Q38374889"
Jump to navigation
Jump to search
The following pages link to OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. (Q38374889):
Displaying 50 items.
- New strategies in immunotherapy for non-small cell lung cancer (Q26775385) (← links)
- Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect (Q26775578) (← links)
- Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination (Q28074536) (← links)
- Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond (Q28077815) (← links)
- The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses (Q36940326) (← links)
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. (Q37158481) (← links)
- Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression (Q37428061) (← links)
- Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4 and CD8 T Cell Responses against Mouse Cytomegalovirus Infection (Q37651700) (← links)
- Immunotherapies for bladder cancer: a new hope. (Q38587157) (← links)
- Advances in Immunotherapy for Melanoma: A Comprehensive Review. (Q38636521) (← links)
- The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice (Q38684474) (← links)
- Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future (Q38687631) (← links)
- Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors (Q38838643) (← links)
- Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma (Q38955815) (← links)
- Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines (Q39189908) (← links)
- Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8 T cells. (Q39559063) (← links)
- Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells (Q40309584) (← links)
- CD8 T Cells That Coexpress RORγt and T-bet Are Functionally Impaired and Expand in Patients with Distal Bile Duct Cancer. (Q40385196) (← links)
- Functional Detection of TNF Receptor Family Members by Affinity-Labeled Ligands (Q41192295) (← links)
- Pan-urologic cancer genomic subtypes that transcend tissue of origin (Q41243664) (← links)
- Editorial: Advances in Combination Tumor Immunotherapy (Q42047687) (← links)
- Advances in lung cancer with a focus on ATS 2016 updates (Q42346091) (← links)
- Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy (Q42660142) (← links)
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'. (Q46527001) (← links)
- Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications (Q47325431) (← links)
- PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions (Q47849021) (← links)
- Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies (Q47936526) (← links)
- Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression (Q47950137) (← links)
- Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking (Q48112970) (← links)
- Current Strategies to Enhance Anti-Tumour Immunity. (Q52344613) (← links)
- Immune checkpoint pathways in non-small cell lung cancer. (Q52581741) (← links)
- Next generation of immune checkpoint therapy in cancer: new developments and challenges. (Q52653710) (← links)
- Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). (Q52683991) (← links)
- Overview of Basic Immunology for Clinical Investigators. (Q52699143) (← links)
- Renal cell carcinoma: a review of biology and pathophysiology. (Q52724797) (← links)
- Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells. (Q55284399) (← links)
- Next generation immune-checkpoints for cancer therapy. (Q55383705) (← links)
- Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. (Q55386131) (← links)
- Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. (Q55503616) (← links)
- Immunotherapy for Gastric Cancer: Time for a Personalized Approach? (Q55652343) (← links)
- Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer (Q56891212) (← links)
- The promise and challenges of immune agonist antibody development in cancer (Q56891562) (← links)
- Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity (Q57297104) (← links)
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy (Q57394699) (← links)
- The clinical promise of immunotherapy in triple-negative breast cancer (Q60045735) (← links)
- Fates of CD8 T cells in Tumor Microenvironment (Q60313339) (← links)
- CD8 T Cells Cry for CD4 Help (Q64074229) (← links)
- ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity (Q64279107) (← links)
- Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. (Q64989852) (← links)
- Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies (Q89217952) (← links)